Show
Sort by
-
- Journal Article
- A1
- open access
A complement atlas identifies interleukin-6-dependent alternative pathway dysregulation as a key druggable feature of COVID-19
-
- Journal Article
- A1
- open access
Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment
-
- Journal Article
- A1
- open access
Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19 : an open-label randomized controlled trial
-
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID) : a factorial, randomised, controlled trial
-
- Journal Article
- A1
- open access
Case report : convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19